Accepted for Publication: March 11, 2021.
Published Online: May 10, 2021. doi:10.1001/jamaneurol.2021.1116
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Brandt AU et al. JAMA Neurology.
Corresponding Author: Michael Demetriou, MD, PhD, Department of Neurology, University of California, Irvine, 208 Sprague Hall, Irvine, CA 92697 (email@example.com).
Author Contributions: Drs Brandt and Demetriou had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Brandt, Sy, Dennis, Paul, Demetriou.
Acquisition, analysis, or interpretation of data: Brandt, Bellmann-Strobl, Newton, Pawling, Zimmermann, Yu, Chien, Dörr, Wuerfel, Dennis, Paul, Demetriou.
Drafting of the manuscript: Brandt, Sy, Yu, Chien, Demetriou.
Critical revision of the manuscript for important intellectual content: Sy, Bellmann-Strobl, Newton, Pawling, Zimmermann, Chien, Dörr, Wuerfel, Dennis, Paul, Demetriou.
Statistical analysis: Brandt, Yu.
Obtained funding: Brandt, Paul, Demetriou.
Administrative, technical, or material support: Bellmann-Strobl, Newton, Zimmermann, Chien, Dörr, Wuerfel, Dennis, Paul.
Supervision: Brandt, Sy, Wuerfel, Dennis, Paul, Demetriou.
Conflict of Interest Disclosures: Dr Brandt reported receiving grants and personal fees from Guthy Jackson Foundation, Einstein Foundation, BMB, and Deutsche Forschungsgemeinschaft Exc 157 during the conduct of the study; being cofounder and receiving shares from Motognosis GmbH and Nocturne GmbH outside the submitted work; and having a patent for GlcNAc as Serum Biomarker for Multiple Sclerosis issued. Dr Sy reported having an ownership stake in Glixis Therapeutics LLC outside the submitted work. Dr Bellmann-Strobl reported receiving nonfinancial support from Biogen Idec; personal fees from Bayer Healthcare, Merck Serono, Teva Pharmaceuticals, Roche, and Novartis; and personal fees and nonfinancial support from Sanofi Genzyme outside the submitted work. Dr Zimmermann reported receiving grants from Novartis and personal fees from Bayer Healthcare outside the submitted work. Ms Chien reported receiving speaking fees from Bayer and research funding from Novartis unrelated to this study. Dr Dörr reported receiving grants from Bayer during the conduct of the study; and personal fees from Bayer, Biogen, Novartis, Roche, Merck Serono, Sanofi, and Teva outside the submitted work. Dr Wuerfel reported receiving grants from the EU (Horizon2020) and the Swiss National Science Foundation; and serving on advisory boards for Actelion, Genzyme-Sanofi, Idorsia, InmuneBio, Novartis, and Roche. Dr Dennis reported holding a patent pending for PCT/US16/15807 N-Acetyl Glucosamine as a Biomarker of MS Disease Course and being an inventor on this patent, a patent on methods and compositions for preventing and treating a disease related to glycan dysregulation issued to Wellsley Therapeutics, and a patent on Analogs of N-acetylglucosamine pending; and being a cofounder of and holding shares in Glixis Therapeutics LLC. Dr Paul reported receiving grants from Celgene, Novartis, BMBF, Alexion, Guthy Jackson Foundation, Falck-Foundation, Roche, Almirall, Deutsche Forschungsgemeinschaft, Einstein Foundation, Biogen, and Merck Serono; research support and personal fees from UCB, Roche, Alexion, Sanofi Genzyme, Mitsubishi Tanabe, Bayer, Merck Serono, and Viela Bio outside the submitted work. Dr Demetriou reported receiving grants from the National Institute of Allergy and Infectious Disease and the National Center for Complementary and Integrative Health during the conduct of the study; having a patent for US9775859B2 issued, a patent for US10495646B2 issued, and a patent pending for US20170042919A1; and being a cofounder and shareholder of Glixis Therapeutics. No other disclosures were reported.
Funding/Support: The UC Irvine discovery cohort was supported by grant R01AI108917 from the National Institute of Allergy and Infectious Disease and grant R01AT007452 from the National Center for Complementary and Integrative Health (Dr Demetriou). The confirmation cohort study was supported by DFG grant Exc. 257 (Dr Paul).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Cynthia Kraut, Technical Radiology Assistant, Charité–Universitätsmedizin Berlin, and Susan Pikol, Technical Radiology Assistant, Charité–Universitätsmedizin Berlin, for MRI assistance and Bibiane Seeger, Laboratory Assistant, Charité–Universitätsmedizin Berlin, and Carey F. Li, PhD, University of California, Irvine, for laboratory assistance. They were all compensated for their work as employees of their respective institutions. We thank Claudia Kawas, for access to participants from the 90+ Cohort.
BAC , Hollenbach
JA , Bove
et al; University of California, San Francisco MS-EPIC Team. Silent progression in disease activity–free relapsing multiple sclerosis. Ann Neurol
. 2019;85(5):653-666. doi:10.1002/ana.25463
IJ , Chen
HL , Demetriou
M . Lateral compartmentalization of T cell receptor versus CD45 by galectin-N
-glycan binding and microfilaments coordinate basal and activation signaling. J Biol Chem
. 2007;282(48):35361-35372. doi:10.1074/jbc.M706923200
RW , Mkhikian
H , Grigorian
et al. N
-glycosylation bidirectionally extends the boundaries of thymocyte positive selection by decoupling Lck from Ca2+
signaling. Nat Immunol
. 2014;15(11):1038-1045. doi:10.1038/ni.3007
L , Khim
P , Mkhikian
H , Mortales
CL , Demetriou
M . Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N
. 2017;6:6. doi:10.7554/eLife.21330
CL , Lee
SU , Manousadjian
A , Hayama
KL , Demetriou
M . N
-glycan branching decouples B cell innate and adaptive immunity to control inflammatory demyelination. iScience
. 2020;23(8):101380. doi:10.1016/j.isci.2020.101380
A , Araujo
L , Naidu
NN , Place
DJ , Choudhury
B , Demetriou
M . N
-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis. J Biol Chem
. 2011;286(46):40133-40141. doi:10.1074/jbc.M111.277814
P , Infante-Duarte
C , Ivaldi
et al. Effect of vitamin D supplementation on N
-glycan branching and cellular immunophenotypes in MS. Ann Clin Transl Neurol
. 2020;7(9):1628-1641. doi:10.1002/acn3.51148
Y , Yu
X , Ichikawa
et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol
. 2014;133(5):1400-1409, 1409.e1-1409.e5. doi:10.1016/j.jaci.2014.02.013PubMedGoogle ScholarCrossref
FD , Reingold
SC ; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology
. 1996;46(4):907-911. doi:10.1212/WNL.46.4.907
Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(pt 5):871-882.
Roxburgh RHSR, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144-1151.
Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage. 2011;56(3):907-922.
Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002;17(1):479-489.
N , Stromillo
ML , Giorgio
et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry
. 2016;87(1):93-99.PubMedGoogle Scholar
Dörr J, Wernecke KD, Bock M, et al. Association of retinal and macular damage with brain atrophy in multiple sclerosis. PLoS One. 2011;6(4):e18132.
AM , Ryczko
M , Pawling
J , Dennis
JW . Probing the hexosamine biosynthetic pathway in human tumor cells by multitargeted tandem mass spectrometry. ACS Chem Biol
. 2013;8(9):2053-2062. doi:10.1021/cb4004173
RG , Shieh
M , Okuda
DT , Evangelista
A , Gorno-Tempini
ML , Pelletier
D . Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry
. 2008;79(11):1236-1244. doi:10.1136/jnnp.2007.134825
A , Escano
MF , Eno
et al. Evaluation of the effect of aging on retinal nerve fiber layer thickness measured by optical coherence tomography. Ophthalmologica
. 2003;217(4):273-278. doi:10.1159/000070634
SK , Potvin
B , Carlsson
S , Sturm
D , Leffler
H , Stanley
P . Complex N
-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells. Glycobiology
. 2006;16(4):305-317. doi:10.1093/glycob/cwj063